Ankita Upadhyay

businessline

Pay disparity: Why young MBBS doctors are protesting in Lucknow

By: Ankita Upadhyay

The agitation began after doctors approached the Directorate General of Medical Education (DGME) and the Directorate General of Health Services (DGHS) seeking an explanation for the disparity

businessline

Experts warn of weaker oversight of medical colleges after NMC scraps 2023 standards rules

By: Ankita Upadhyay

Physical inspections had already become less frequent for some processes, such as applications to add seats in existing colleges, making it harder to catch “ghost faculty” or claimed infrastructure that does not exist

businessline

Delhi’s primary healthcare network shrinks 38%; hospital OPD, school clinic visits fall

Delhi’s primary care shrinks 38% amid declining hospital and school clinic visits, with resource constraints and leprosy programme underspending flagged.

businessline

Cancer drug price controls won't address wider problem of overpriced medicines: Petitioner in SC

By: Ankita Upadhyay

Since the majority of drugs fall in the non-scheduled category, he urged the ministry to use its Clause 19 powers beyond cancer medicines

businessline

Cancer drug price cap: Despite steepest cuts on generics, biosimilars, most patented, single-brand drugs keep their prices

By: Ankita Upadhyay

35 drugs get cheaper across the board, 47 stay unchanged, and cuts reach 93% on some brands

Cancer drug price cap: Despite steepest cuts on generics, biosimilars, most patented, single-brand drugs keep their ...

By: Ankita Upadhyay

businessline

Indian patent office rejects TB Alliance's patent for Drug-Resistant TB treatment

By: Ankita Upadhyay

Patient groups opposed the application, arguing that the drug combination was already known. The decision could help improve access to affordable treatment.

businessline

Healthcare leaders question govt treatment rates, call for scientific costing studies

By: Ankita Upadhyay

Healthcare leaders urge scientifically grounded costing for government treatment rates, linking affordability, quality, and fair reimbursement across India’s care landscape.

businessline

Patented, single source cancer drug prices remain unchanged under 30% margin cap, NPPA data shows

By: Ankita Upadhyay

NPPA data show most single-source cancer drug prices remained unchanged under a 30% trade-margin cap, questioning the measure’s impact on costly patented therapies.

businessline

For years, some cancer drugs cost up to 15 times their new price

By: Ankita Upadhyay

Of the 397 brands whose price fell, 217 were at least twice as expensive as their revised price, and 120 were at least three times as expensive